A new FDA guidance on Bayesian statistics is poised to broaden how sponsors design clinical trials, particularly for diseases where uncertainty, heterogeneity, and rare-event dynamics complicate conventional approaches. The FDA’s focus on Bayesian methods signals an openness to flexible designs that may reduce development cost and time. For sponsors planning oncology and rare disease programs, Bayesian frameworks can affect interim decision-making, adaptive enrollment strategies, and how evidence is accumulated across time. That can translate into fewer participants or faster endpoint evaluation if regulatory expectations align. The FDA’s stance is likely to influence clinical-statistics vendors, CRO trial methodology, and how protocols are drafted for upcoming submissions—especially where traditional fixed design assumptions underperform.